A cute ST-segment-elevation myocardial infarction (STEMI) is a major cause of morbidity, mortality, and disability worldwide. For the past years, the management of patients with STEMI has considerably evolved in terms of reperfusion strategies, adjunctive antithrombotic therapy, technical approaches, and development of coordination systems of care. This effort has not only led to a marked reduction in clinical event rates, but also resulted in continuous paradigm shift on our approach to treating these patients.
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The rapidity with which new information from pivotal trials and registries becomes available makes it a challenge for clinical guidelines to stay current because these documents inevitably lag behind the most recent reported findings in the field. This also presents a challenge for physicians because it is not always clear on how such emerging evidence should be embraced in clinical practice without endorsement from our professional societies. In this Editorial viewpoint, we put into perspective some of the recent pivotal data that have emerged and influences our clinical practice in the percutaneous management of patients with STEMI. [1] [2] [3] In particular, areas that have evolved in percutaneous management of patients with STEMI include appropriate device use, revascularization strategies in the catheterization laboratory, and setting up optimal benchmarks and systems of care.
In the device arena, current guidelines give a class IIa (level of evidence B) recommendation to the use of manual aspiration thrombectomy in patients undergoing primary percutaneous coronary intervention (PCI). 4, 5 This recommendation has been primarily derived from the findings of the Thrombus Aspiration during Percutaneous Coronary Intervention in Acute Myocardial Infarction Study (TAPAS) trial, showing that in patients with STEMI undergoing primary PCI (n=1071), manual aspiration was not only associated with better reperfusion, but also improved long-term outcomes, including mortality. 6 This has fueled the field of investigation with aspiration techniques that have been embraced with enthusiasm by interventionalists, who in many cases have made manual aspiration a routine part of their practice when performing primary PCI. However, such enthusiasm for the routine use of manual aspiration devices has been recently tempered by the results of the Thrombus Aspiration in ST-Elevation Myocardial Infarction in Scandinavia (TASTE) trial. 1 This large-scale registry-based clinical trial enrolling 7244 patients with STEMI undergoing primary PCI randomized to receive manual thrombus aspiration followed by PCI or primary PCI only showed that the effect of thrombus aspiration was neutral on the primary end point of 30-day mortality (2.8% versus 3%; P=0.63), and this finding was consistent across all prespecified subgroups and involving all secondary end points. The benefit of such a large-scale study is that it sends a clear signal on hard-end points, such as mortality, not relying on surrogates, such as markers of perfusion, which have been the outcome measure of prior small sample-sized studies addressing this issue. However, it should be noted that the 30-day follow-up might not have been long enough to show clinical efficacy, which in prior studies was observed only at 6 to 12 months. 6, 7 The longterm data from the TASTE trial and the results of the ongoing TOTAL (Routine Aspiration Thrombectomy With PCI Versus PCI Alone in Patients With STEMI Undergoing Primary PCI; NCT01149044) trial (n=4000) will provide more insights on the role of aspiration thrombectomy during primary PCI. Until then, the routine use of manual aspiration devices must be questioned.
Our current coronary revascularization guidelines have also been recently challenged. Approximately two thirds of patients undergoing primary PCI have multivessel coronary artery disease. Although it is known that these patients have a worse prognosis, the optimal revascularization plan for this population remains not fully understood. 8, 9 Potential revascularization strategies include: (1) culprit vessel-only PCI strategy, defined as PCI confined to the infarct-related lesion only;
(2) staged PCI strategy, defined as PCI confined to the culprit vessel, after which non-culprit vessel lesions are treated during staged procedures; (3) multivessel PCI strategy, defined as PCI of the culprit vessel and all other non-culprit vessel lesions at the time of primary PCI. Current guidelines recommend that PCI should not be performed (class III) in a noninfarct artery at the time of primary PCI in patients with STEMI who are hemodynamically stable. 4, 5 Recently, the concept of revascularization of the infarct-related artery only has been challenged in the Preventive Angioplasty in Acute Myocardial Infarction (PRAMI) trial, in which a strategy of preventive PCI (multivessel revascularization performed at the time of primary PCI on all vessels with angiographic stenosis ≥50%) was tested against culprit vessel-only strategy in patients with STEMI (n=465) undergoing primary PCI. 2 The trial was stopped prematurely because of a significant reduction in the primary outcome (a composite of cardiac death, nonfatal MI, or refractory angina) in the preventive PCI group at a mean follow-up of 23 months (9% versus 23%; P<0.001). The benefit achieved with complete revascularization was also similar for the composite outcome of cardiac death and nonfatal MI. The impressive magnitude of this treatment effect is unusual in clinical trials: an absolute risk reduction of 14% accompanied by no apparent increase in procedural risk. These findings potentially may prompt many practitioners to shift their revascularization approach when performing primary PCI in the setting of multivessel coronary artery disease. However, the PRAMI trial does have some limitations and we await possible confirmatory findings from the ongoing Complete versus Culprit-only Revascularization to Treat Multi-vessel Disease After Primary PCI for STEMI (COMPLETE) trial (NCT01740479). This trial will assess whether, on a background of optimal medical therapy with aspirin and ticagrelor, a strategy of complete revascularization involving staged PCI using drug-eluting stents of all suitable non-infarct-related artery lesions is superior to a strategy of culprit vessel-only PCI, after successful primary PCI for STEMI (n=3900). The study will also importantly integrate fractional flow reserve into the treatment algorithm. This treatment strategy can indeed be a possible game changer that may affect not only practice guidelines, but also judiciously performed same setting multivessel PCI in a primary PCI setting can potentially affect long-term outcomes, resource use, and patient satisfaction.
A great deal of resources has been expended best to develop benchmarks and systems facilitating the delivery of timely care to patients with STEMI. In particular, the metric in which we have placed the most emphasis and effort has been the door-to-balloon time. 4, 5 Door-to-balloon times have represented a moving target and we have achieved great success reaching benchmarks in this final phase of precatheterization laboratory treatment. There has been an almost obsessive agenda to bring patients to the catheterization laboratory in the most expeditious way. As a result of this strive for timing, judicious clinical evaluation is sometimes euthanized. One third of STEMI activations are now false alarms, representing an important unintended consequence of this strategy. 10 This has placed unusual strain on medical care providers and hospital systems. A recent report from the CathPCI Registry of the National Cardiovascular Data Registry conducted on 96 738 admissions for primary PCI across the United States between 2005 and 2009 showed that absolute door-to-balloon times and the rate of patients with door-to-balloon times ≤90 minutes (from 59.7% to 83.1%) has decreased significantly, 3 no doubt related to cumulative efforts to achieve these goals. Nevertheless, this success was not associated with a reduction in in-hospital and 30-day mortality rates, suggesting that additional factors should be targeted to reduce mortality. We now appreciate that door-to-balloon time is only one of many components (occurring late in the precatheterization chain of events) of timely revascularization. Therefore, efforts and resources might be better spent on strategies aimed to reduce prehospital timing, such as interhospital transfer time or time from symptom onset to first medical contact. Indeed, this will represent our next timing challenge in STEMI care.
In conclusion, we have recently been enlightened by 3 relevant reports that may substantially modify our revascularization approach to patients with STEMI. In an era in which we are expected to practice quality and value-based medicine, these data will potentially help achieve these goals. It is inevitable that advancements in the field will lead to paradigm shifts in STEMI management and unravel new challenges in our current quality and cost conscious environment.
